Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switching Antipsychotics May Not Be Best Option, New CATIE Analysis Finds

Executive Summary

Ongoing analyses of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) continue to support a benefit for Lilly's Zyprexa over other antipsychotic medications, with the latest trial results showing that Zyprexa is the only atypical where patients did better by remaining on the drug

You may also be interested in...



CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals

The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program

Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge

The superiority of Novartis' Clozaril over second-generation antipsychotics in the second phase of the National Institute of Mental Health's CATIE trial suggests the need to manage the serious side effects of clozapine therapy while expanding its use, study authors argue

CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM

Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study

Related Content

UsernamePublicRestriction

Register

PS047835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel